trial · primary record
Anumigilimab
Sickle Cell Disease
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 63 |
| Primary completion | 2028-08-15 |
| Primary endpoint | Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP) |
| Registry ID | NCT07224360 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:31.829Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07224360
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.